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Background: Insomnia symptoms are a common form of sleep difficulty among people with type 2 diabetes (T2D) affecting
sleep quality and health outcomes. Several interventional approaches have been used to improve sleep outcomes in people with
T2D. Nonpharmacological approaches, such as cognitive behavioral therapy for insomnia (CBT-I), show promising results
regarding safety and sustainability of improvements, although CBT-I has not been examined in people with T2D. Promoting
sleep for people with insomnia and T2D could improve insomnia severity and diabetes outcomes.
Objective: The objective of this study is to establish a protocol for a pilot randomized controlled trial (RCT) to examine the
effect of 6 sessions of CBT-I on insomnia severity (primary outcome), sleep variability, and other health-related outcomes in
individuals with T2D and insomnia symptoms.
Methods: This RCT will use random mixed block size randomization with stratification to assign 28 participants with T2D and
insomnia symptoms to either a CBT-I group or a health education group. Outcomes including insomnia severity; sleep variability;
diabetes self-care behavior (DSCB); glycemic control (A1c); glucose level; sleep quality; daytime sleepiness; and symptoms of
depression, anxiety, and pain will be gathered before and after the 6-week intervention. Chi-square and independent t tests will
be used to test for between-group differences at baseline. Independent t tests will be used to examine the effect of the CBT-I
intervention on change score means for insomnia severity, sleep variability, DSCB, A1c, fatigue, sleep quality, daytime sleepiness,
and severity of depression, anxiety, and pain. For all analyses, alpha level will be set at .05.
Results: This study recruitment began in February 2019 and was completed in September 2019.
Conclusions: The intervention, including 6 sessions of CBT-I, will provide insight about its effect in improving insomnia
symptoms, sleep variability, fatigue, and diabetes-related health outcomes in people with T2D and those with insomnia symptoms
when compared with control.
Trial Registration: ClinicalTrials.gov NCT03713996; https://clinicaltrials.gov/ct2/show/NCT03713996
International Registered Report Identifier (IRRID): DERR1-10.2196/14647
(JMIR Res Protoc 2019;8(12):e14647)  doi: 10.2196/14647
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Introduction
Background
Type 2 diabetes (T2D) is the predominant form of diabetes
mellitus that results in multiple complications, including sleep
difficulties [1]. It is a global health issue primarily affecting
older adults [2]. It results from relative insulin deficiency and
peripheral insulin resistance [3]. Consequently, T2D causes
abnormal amounts of glucose in the bloodstream [4]. As a result,
T2D has been linked to several complications including
hyperglycemia, which may also affect multiple organs and
systems [5]. As a result, hyperglycemia may lead to sleep
disturbances because of associated symptoms, including
headache, increased thirst, and nocturia [6].
Sleep disturbances have been shown to increase activation of
the hypothalamic-pituitary-adrenal (HPA) axis [7], which may
further exacerbate the management of T2D [8]. During a night
of poor sleep, cortisol levels increase because of hyperactivation
of the stress system HPA, which then leads to an increased
glycation level in the blood stream [9]. As individuals with T2D
are particularly susceptible to hyperglycemia, an increased
glycation level may be particularly problematic [10]. To
illustrate that, increasing the glucose level during a night of
sleep in people with T2D may increase the bathroom visits and
the number of awakenings [11]. Increasing the number of
awakenings during a night of sleep is a part of poor sleep quality
[12], which may further contribute in activation of the stress
system [13]. This might suggest a bidirectional relationship
between sleep disturbances and hyperglycemia [14].
Compounding this issue even further, previous research has
shown that rates of several sleep disorders including obstructive
sleep apnea, insomnia, and restless leg syndrome (RLS) are
increased in people with T2D [15-17]. After controlling for age
and gender, the prevalence of insomnia diagnosis is significantly
higher in people with T2D, compared with those without it
[15,17,18].
Insomnia is one of the most common sleep disorders in people
with T2D, as more than half of their population report insomnia
symptoms [17,18]. In a study of people with T2D, 8% to 17%
reported difficulty falling asleep, 23% to 40% reported difficulty
staying asleep, and 26% to 43% reported difficulty in both
initiating and maintaining sleep [17]. In another study of 7239
individuals with T2D, 76.8% of that sample reported
experiencing insomnia symptoms regularly. For those 7239
individuals, the 3 most prevalent insomnia symptoms were
nocturia (43.8%), difficulty falling asleep (30.5%), and waking
after sleep onset (WASO; 27.0%) [15,17].
For adults and older adults diagnosed with clinical insomnia,
there are several negative effects of insomnia that are harmful
to long term health, such as increases in daytime sleepiness, fall
risk, fatigue, and a decline in the quality of life [19,20].
Furthermore, studies have reported that insomnia is associated
with hypertension, diabetes, and cardiovascular disease [20-22].
Consequently, insomnia increases the risk of all-cause mortality
3-fold over a 15-year follow-up period [23].
Although individuals with T2D or insomnia are at increased
risk of negative health outcomes, there are also unique risks to
those who have both T2D and insomnia. People with T2D who
experience poor sleep quality or excessive daytime sleepiness
show decreased adherence to diabetes self-care behavior (DSCB)
[24]. DCSB is essential in maintaining or attaining glycemic
control (A1c) in people with T2D [25]. Sleep quality and low
sleep variability are also important for well-being and a healthy
life [26,27]. Indeed, poor health and quality of life are thought
to be associated with poor sleep quality in people with T2D
[28-30]. In addition to deficits in sleep quality, high sleep
variability is common in people with insomnia [31] and, may
be, even more prominent in people with T2D [32]. Furthermore,
it has been found that variability of bedtime and wake time is
associated with a high level of the inflammatory biomarker
called tumor necrosis factor (TNF)-alpha in people with and
without insomnia [33]. TNF-alpha is associated with vascular
diseases, such as atherosclerosis [34].
T2D and insomnia have a bidirectional relationship, which
might be because of shared risk factors [8]. Risk factors that
are commonly reported by people with both T2D and insomnia
include depression, anxiety, pain, and obesity [8,19,35,36].
These health issues may exacerbate the severity of insomnia
symptoms, and they may add complexity to A1c [37,38].
Although several studies have examined the complex
relationship between T2D and insomnia while controlling for
risk factors, the underlying mechanisms of this relationship are
still under investigation. Although this investigation is still in
its infancy, examining the effect of treating insomnia symptoms
may reveal important information for people with T2D in future
studies.
Pharmacological approaches for treating insomnia have
potentially serious side effects on health. Several studies have
shown an association between sleeping pill prescriptions and
mortality in different populations [39-44]. Different sleep
medications were associated with increased risk of fall [45],
motor vehicle accidents [46], and suicidality [47]. Individuals
with insomnia who use benzodiazepines or nonbenzodiazepines
are at high risk of developing T2D because of potential changes
in insulin secretion and sensitivity [48,49]. It is a widely held
view that sleep apnea is a prevalent sleep disorder in people
with T2D [50]. A possible explanation of increasing the severity
of sleep apnea is that hypnotics are respiratory suppressants that
might contribute in vital health issues for this population [51].
The insulin sensitivity improved in people with severe sleep
apnea after receiving sleep hygiene, dietary counseling, and
continuous passive airway pressure (CPAP) support, which
suggests that the metabolic function in people with T2D might
be improved by a sleep promotion program [52]. Thus, it is
important to identify safe and effective nonpharmacological
treatments for people with T2D and insomnia symptoms.
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The American Academy of Sleep Medicine recommends
cognitive behavioral therapy for insomnia (CBT-I) as the first
line of treatment for people with insomnia [53]. A meta-analysis
has shown CBT-I to produce clinically meaningful
improvements in sleep outcomes including sleep latency (SL),
sleep efficiency (SE), number of awakenings, and total sleep
time (TST) [54]. In addition, CBT-I is designed to change sleep
habits as well as address misconceptions about sleep and
insomnia [55]. CBT-I is superior to sleep medications in terms
of cost and long-term benefits [55]. Although there is currently
limited evidence about the effect of CBT-I on people with T2D,
CBT-I is a potentially effective intervention given insomnia’s
relationship with glucose metabolism. We anticipate that CBT-I
components will disrupt the associated physiological
mechanisms between insomnia and T2D. Sleep restriction and
stimulus control therapies are helpful in strengthening sleep
homeostasis [56], which is also associated with the glucose
regulation [57]. In adults with sleep restriction, increasing the
TST with a simple low-cost intervention was associated with
improvements in fasting insulin sensitivity [58]. Relaxation
techniques are designed to minimize stress [59], which has a
negative impact on the HPA axis in people with T2D [60]. These
techniques are important additions in the treatment plan because
of the high prevalence of psychological disorders such as
depression and anxiety in people with T2D and insomnia [61].
The evidence has shown that sleep hygiene is not effective as
monotherapy [62]. However, several items in the sleep hygiene
could trigger DSCB, such physical activity, water consumption,
and food schedule [30]. For example, avoiding excessive drinks
at a night might help people with T2D minimize the bathroom
visits after sleep onset [63]. The presence of nocturia is
commonly reported in people with T2D, which could be one of
the leading symptoms of insomnia [64]. CBT-I could compress
the fragmentation of sleep, which may eventually help in
reducing nocturia [64].
Objectives and Hypotheses
The primary objective of this study is to establish a protocol for
a pilot study to (1) investigate the effect of 6 sessions of CBT-I
on insomnia severity in people with T2D and insomnia
symptoms and (2) explore the effect of 6 sessions of CBT-I on
sleep variability; fatigue; A1c; DSCB; sleep quality; daytime
sleepiness; and the severity of depression, anxiety, and pain in
people with T2D and insomnia symptoms. We hypothesized
that people in the CBT-I group will have greater improvement
in insomnia severity, sleep variability, fatigue, A1c, DSCB, sleep
quality, daytime sleepiness, and severity of depression, anxiety,
and pain compared with people receiving only health education
(HE). We anticipate the improvement in insomnia severity will
positively impact people with T2D and health outcomes because




The study design will be a pilot randomized controlled trial
(RCT). This study will have an allocation ratio of 1:1, and this
pilot RCT will be using a superiority framework to test the
effectiveness of the experimental CBT-I intervention. This
protocol is in accord with the Standard Protocol Items:
Recommendations for Interventional Trials 2013 statement [65],
and the intervention will be described according to the
Consolidated Standards of Reporting Trials 2010 guideline [66].
Participants, Interventions, and Outcomes
Study Setting
This study will be conducted at the University of Kansas
Medical Center (KUMC) in the United States. The study sites
are also listed on ClinicalTrials.gov [67].
Eligibility Criteria
The inclusion and exclusion criteria are shown in Textboxes 1
and 2.
Textbox 1. Inclusion criteria.
• Aged between 40 and 75 years.
• Have a type 2 diabetes diagnosis.
• Have a score of >10 on Insomnia Severity Index that indicates clinical insomnia—in addition, we will ask for reported symptoms of difficulty
falling asleep, maintaining sleep, or waking up too  early at least three nights/week for the past 3 months.
• Are able to understand and follow verbal commands in English—the intervention and  questionnaires are available in English only; therefore,
the participants must understand English language.
• Are able to travel to the University of Kansas Medical Center to attend all assessment and intervention  visits at  the Health Exercise and Aging
Lab.
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Textbox 2. Exclusion criteria.
• Self-reported neurological diseases (eg, Alzheimer disease, Parkinson disease, traumatic brain injury, stroke, and multiple sclerosis)
• A score >4 on Stop-Bang questionnaire
• Failure to pass Restless Leg Syndrome Diagnostic Index
• Brief Pain Inventory score ≥7
• Beck Depression Scale score ≥21
• Generalized Anxiety Disorder–7 score ≥15
• Pregnant women
• Self-reported the following medical issues: chronic fatigue syndrome, fibromyalgia, bipolar, seizure disorders, and rheumatic diseases
• Speech deficits or significant auditory impairment
• Current night shift work
• Heavy alcohol drinker (≥15 drinks per week for men and ≥8 for women)
• Dialysis, blindness, or transfemoral amputation
In addition, during the phone screening, we will exclude the
following people: 1) Those with scores >4 on Stop Bang items
including snoring, tiredness, observed apnea, blood pressure,
body mass index, age, neck circumference, and gender. People
with sleep apnea symptoms commonly report poor sleep quality
and insomnia [68]. The Snoring, Tiredness, Observed apnea,
Blood pressure, Body mass index, Age, Neck circumference,
and Gender (STOP Bang) questionnaire will be used to screen
the common symptoms related to the high risk of sleep apnea,
such as the presence of snoring behavior, wake time sleepiness
or fatigue, and history of obesity or hypertension [69]. Neck
circumference will be measured in the active screening session.
STOP Bang showed higher sensitivity and specificity (93% and
28%, respectively), compared with other screening
questionnaires at polysomnography-derived apnea-hypopnea
index (score of 15), which indicates severe sleep apnea [70]. In
addition, a meta-analysis [71] recommended using the
STOP-Bang questionnaire as a screening for sleep apnea. If
interested subjects have positive scores for 5 or more categories,
they are classified as being at high risk of sleep apnea [69].
Those subjects will be excluded and recommended to visit their
sleep specialists. We expect some people are diagnosed with
sleep apnea and they are adhered with their CPAP machine.
Those people will be still included by asking them to answer
the STOP Bang questionnaire with considering CPAP
utilization; 2) those failing to pass the RLS Diagnostic Index
[72]. The RLS Diagnostic Index is based on an algorithm to
give yes or no conclusion regarding the presence of RLS. The
RLS Diagnostic Index includes questions about the urge to
move legs or arms to detect the risk of RLS symptoms [72]. If
the RLS Diagnostic Index indicates higher RLS risk, individuals
fail the RLS Diagnostic Index, as RLS has a negative impact
on individuals’ sleep, specifically, insomnia [73]; 3) those who
are pregnant. As pregnancy impacts sleep, and insomnia is one
of the major problems experienced in pregnancy, individuals
who are pregnant will be excluded to reduce potential
confounding factors [74]; 4) those who are heavy alcohol
drinkers. In accordance with definitions established by the
National Institute of Alcohol Abuse and Alcoholism [75], heavy
drinking is typically defined as consuming 15 drinks or more
per week for men and 8 drinks or more per week for women.
Heavy alcohol consumption has been shown to be associated
with sleep complaints among adults [76]. In addition, heavy
drinking has been shown to be associated with subsequent
insomnia symptoms in adults aged between 40 and 60 years
[76]. Therefore, heavy alcohol drinkers will be excluded to
reduce potential confounding factors; 5) those having any of
the following self-reported problems: Neurological
diseases—people with previous neurological disorders (eg,
multiple sclerosis, Alzheimer disease, Parkinson disease,
traumatic brain injury, and stroke—people with these
neurological disorders usually report sleep problems [77-81].
Therefore, we want to focus on the interaction between insomnia
and T2D; bipolar and seizure disorders—people with bipolar
disorder and seizure disorder have complex sleep problems
other than insomnia [82,83]. Furthermore, CBT-I is
contraindicated for these populations [84]; chronic fatigue
syndrome, fibromyalgia, and rheumatic diseases—people
chronic fatigue syndrome is a medically unexplained disabling
illness with nonrestorative sleep and potentially extended sleep
duration [85]. Pain, fatigue, and poor sleep quality are common
symptoms in people with fibromyalgia and rheumatic diseases
[86-90]. Therefore, people with chronic fatigue syndrome,
fibromyalgia, or rheumatic diseases will be excluded in this
study; and dialysis, blindness, and transfemoral
amputation—these diabetes complications may restrict people
with T2D from performing components related to CBT-I; and
6) those who are shift workers. Shift workers usually report
more physical and psychological distress, insomnia, and stress
than non–shift workers [91]. In addition, CBT-I is
contraindicated for people with shift work because CBT-I might
increase sleepiness, which could put the individual at increased
risk of harm.
During active screening session, the following interested
participants will be excluded: 1) Those having scores ≥7 out of
10 on the Brief Pain Inventory (BPI) [92]. A subject with a
score ≥7 out of 10 indicates severe pain symptoms. Diabetic
patients with severe pain report high symptoms level of anxiety
and depression and poor sleep quality [93]; 2) those having
scores ≥21  on the Beck Depression Inventory (BDI). BDI
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contains 21-item self-report inventory measuring the severity
of depression symptoms in adolescents and adults, and
participants with scores ≥21 indicate severe depression
symptoms because scores above that point suggest severe
symptoms level of depression [94]. Depression may lead to
insomnia [95], and CBT-I may be a contraindication [96] or
lead to contradictory results [97] for people with severe
depression. Therefore, there is a need to exclude those people
with severe symptoms level of depression from this study; 3)
those having scores ≥15 on the Generalized Anxiety Disorder–7
(GAD-7) scale. Subjects who score ≥15 on GAD-7 indicate
severe symptoms level of anxiety [98]. CBT-I is contraindicated
for people with significant anxiety symptoms [96]; and 4) those
having significant uncorrected visual, auditory impairment, and
speech deficits. These health problems may affect the CBT-I
delivery.
In addition, during the active screening session, we will confirm
the ages between 40 and 75 years by obtaining the date of birth.
People with diabetes aged between 40 and 75 years usually
present with chronic insomnia [8,99]. A T2D diagnosis will be
confirmed by each participant’s self-report. A study previously
showed that the specificity of the prevalence and incidence of
self-reported T2D was 84% and 97%, respectively, and
sensitivity was 55% and 80%, respectively, compared with
fasting glucose, A1c, and/or medication use [100]. In addition,
a study suggested that self-reporting of T2D was sufficiently
accurate [101]. In addition to the self-report of T2D diagnosis,
we will also review the medication list to confirm the diagnosis
during the screening active session.
Interventions: Experimental and Health Education
All intervention sessions will be delivered by a trained CBT-I
provider. The CBT-I provider is a physical therapist who
completed coursework and a Mini-Fellowship in Behavioral
Sleep Medicine through the University of Pennsylvania.
Ongoing mentorship will be provided by an experienced CBT-I
provider. All participants will receive 6 sessions over the course
of 6 weeks of either CBT-I or HE (ie, 1 session per week for 6
weeks). Sessions will last for 1 hour for both groups to mitigate
the impact of social interaction. We chose HE sessions as usual
care for people with T2D. Textboxes 3 and 4 describe each
intervention arm with all components. The timeline of each
component for the CBT-I and HE groups is provided in Figures
1 and 2.
Textbox 3. Description of cognitive behavioral therapy for insomnia components.
• Sleep restriction therapy
• Time in bed will be limited to the total sleep time by identifying the wake time and total sleep time to increase the sleep efficiency. We will
not prescribe the total time in bed to be less than 6 hours.
• Stimulus control therapy
• This component strengthens the association between the bedtime and sleep only. We will ask participants to use the bed for only sleep and
sexual activity to help train the brain. Participants will be asked to leave the bedroom if unable to fall asleep within 20 min and return when
sleepy.
• Sleep hygiene
• This component will minimize the influence of negative behaviors on sleep quality and quantity. The principles and the effects of diet,
exercise, caffeine, alcohol, and environment on sleep behavior will be provided.
• Relaxation techniques
• Diaphragmatic breathing technique promotes relaxation by using the diaphragm correctly while breathing.
• Mindfulness reduces cognitive and somatic arousal. The principles of mindfulness (nonjudging, patience, trust, acceptance, and letting go)
will be discussed.
• Progressive muscle relaxation positively influences physiologically measured muscle tension.
• Cognitive therapy changes detrimental beliefs and attitudes about sleep. We will work on reducing sleep effort, catastrophic predictions,
worry about sleep, and fearing of insomnia relapse.
• Insomnia relapse
• This component facilitates the understanding of the risk factors of reoccurrence. We will discuss the approaches to maintain clinical gains.
JMIR Res Protoc 2019 | vol. 8 | iss. 12 | e14647 | p. 5https://www.researchprotocols.org/2019/12/e14647
(page number not for citation purposes)
Alshehri et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Textbox 4. Description of health education components.
• Brief sleep hygiene
• We will discuss 8 items of sleep hygiene including exercise, comfortable bedroom, temperature of bedroom, food, liquids, caffeine, alcohol
consumption, smoking, and naps. Parts of sleep hygiene, such as consistent sleep schedule and association of bed with sleep, will not be
included in this brief sleep hygiene education.
• Foot care education
• We will provide foot care education regarding the demographic and comorbidity, foot pathology and assessment, and preventive interventions.
In addition, we will provide the American Diabetes Association recommendation regarding foot hygiene.
• Causes and diagnosis of diabetes
• We will provide information about diagnosis and classification of diabetes mellitus from the American Diabetes Association. The following
topics will be discussed:
• The definition and description of Diabetes Mellitus, classification of diabetes mellitus, and other categories of glucose regulation
• Categories of increased risk for diabetes
• Diagnostic criteria for diabetes mellitus
• A short animation will be provided to explain how diabetes affects the body
• Healthy diet education
• Different dietary approaches to manage type 2 diabetes will be discussed. Articles from American Diabetes Association website will be
navigated).
• Physical activity education
• We will use a guide for adults based on the 2008 Physical Activity Guidelines for Americans. We will discuss following points: wondering
about how much activity you need each week, want to be physically active but not sure where to begin, and started a program and would
like tips on how to keep it up.
Figure 1. The timeline of the CBT-I (cognitive behavioral therapy for insomnia) intervention.
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Figure 2. The timeline of Health Education.
Experimental Intervention
Participants allocated to the CBT-I group will meet with the
CBT-I provider weekly for 1 hour of CBT-I sessions. CBT-I is
designed to address cognitive and behavioral factors that
perpetuate insomnia [102]. It includes several therapeutic
components including sleep restriction therapy, stimulus control
therapy, sleep hygiene, relaxation techniques, and cognitive
therapy. At each session, the CBT-I provider will ask about any
new difficulties, explain the outline of the session, calculate the
SE of the previous 7 nights of sleep, and close the session with
assessing any concerns and providing a new sleep diary. At
each session, prescribed time in bed and out of bed will be
determined based on calculation for SE of the weekly sleep
diary. SE will be calculated as the ratio of TST and total bed
time multiplied by 100. At each session, if the SE is greater
than 90%, participants will be given the opportunity to go to
bed 15 min earlier. If SE is between 85% and 89.9%,
participants will be asked to remain on the same sleep schedule
as currently prescribed. If it is less than 85%, they will be asked
to move their bedtime 15 min later, although total time in bed
will not be less than 6 hours.
This protocol intervention was designed based on a
session-by-session guide [103].
Session 1 (60-90 Min)
Sleep restriction therapy, stimulus control therapy, and sleep
hygiene will be started in this session. The sleep diary from the
previous week will be reviewed to calculate the average SE
from the previous 7 nights. In this session, subjects will learn
the rationale and efficacy of using sleep restriction therapy and
stimulus control therapy as a first line of treatment. Sleep
restriction therapy is designed for individuals who are not able
to initiate and/or maintain sleep [103,104]. This technique limits
the time in bed to be equivalent to the TST by identifying the
wake time and TST to increase the SE. Stimulus control
promotes sleep drive and reinforces circadian entrainment by
associating the bed to sleep only or for sex [103,104]. By
applying the sleep restriction and stimulus control interventions,
we will set prescribed time in bed and prescribed time out of
bed by using the average of TST from previous week sleep diary
and preferred time to wake up in the morning. Thus, the goal
of this session is to align sleep with the opportunity to sleep,
make plan in staying awake until the prescribed time in bed for
sleep restriction therapy, and provide a list of activities during
awake time or WASO for stimulus control therapy. In addition,
sleep hygiene is implemented to minimize the influence of
negative behaviors on sleep quality and quantity [103,104].
Sleep hygiene focuses on the impacts that diet, exercise,
caffeine, alcohol, and environment can have on sleep [103,104].
Session 2 (30-60 Min)
Sleep titration, reviewing sleep hygiene, and introducing
diaphragmatic breathing technique will be covered in this
session. In this week, we will again review the sleep diary to
confirm any necessary sleep titration (that is sleep restriction
therapy adjustment). Sleep titration will be determined by
measuring the individual’s SE. An SE >90% indicates positive
gain that directs upward sleep opportunity. An SE between 85%
and 90% score indicates marginal gain that maintains the sleep
schedule. An SE <85% score indicates negative gain that directs
downward sleep opportunity. If compliance issues arise during
the sleep diary review, this session will focus on reinforcing
the importance of sleep restriction and stimulus control
therapies. Stress and anxiety symptoms are commonly reported
in people with insomnia [105]. Thus, it is also important to
implement relaxation techniques at the first sessions. We will
emphasis relaxation therapy for people who are not able to relax
because of varied of stressors or being an anxious. One of the
relaxation therapies is the diaphragmatic breathing technique
that promotes muscle relaxation, breathing performance, and
memory relaxation. A brief diaphragmatic breathing handout
and video will be utilized during the session.
Session 3 (30-60 Min)
Similar to sessions 1 and 2, the sleep diary will be reviewed for
sleep titration, and we will introduce mindfulness. Upward or
downward sleep titration will be determined based on the sleep
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diary. Mindfulness has shown positive effects in reducing
cognitive and somatic arousal when combined with CBT-I for
people with insomnia [106]. The principles of mindfulness
(nonjudging, patience, trust, acceptance, and letting go) and its
practice will also be introduced during this session.
Session 4 (30-60 Min)
Sleep titration and progressive muscle relaxation will be
delivered in this session. Upward or downward sleep titration
will be determined based on the sleep diary. Muscle relaxation
therapy is a physiological intervention designed to measure and
reduce muscle tension [107]. In addition, muscle relaxation
therapy has been incorporated with CBT-I to improve insomnia
and depression symptoms [107]. A brief progressive muscle
relaxation handout and video will be utilized during the session.
Session 5 (30-60 Min)
Sleep titration and cognitive therapy will be delivered in this
session. Cognitive therapy is designed to change detrimental
beliefs and attitudes about sleep. The intervention content
provided in sessions 1, 2, 3, or 4 may be similar to the cognitive
therapy provided in session 5, although session 5 will focus on
providing the cognitive therapy intervention in its entirety.
During this session, we will work on reducing sleep effort,
catastrophizing, anxiety about sleep, and insomnia relapse. Also,
we will work on correcting negative sleep beliefs, particularly
regarding insomnia. In addition, we will work on enhancing
individuals’ willingness to modify the sleep-related behaviors
and engage in good strategies. Finally, we will continue working
on sleep titration to optimize the SE.
Session 6 (30 Min)
Assessing global treatment gains and relapse prevention
education will be the focus in this session. We will review the
SE of each session to graphically demonstrate the participant’s
SE over the course of this intervention. This process will help
in providing information that facilitates chronic insomnia and
understands the risk factors of reoccurrence. Finally, we will
discuss the approaches to maintain clinical gains and fix
insomnia returns, and we will schedule participants for the
reassessment session.
During each session, the CBT-I provider will use 2
documentation sheets that are nonspecific to CBT-I: a checklist
and tracking sheet. These sheets will help the CBT-I provider
for quality assurance and standardization of treatment sessions
across participants. We do not expect these sheets to contribute
to the intervention or the outcomes of this study.
The participants will be called 1 day before each session to
confirm their session appointment the following day and remind
them to bring their completed sleep diary. In addition, a folder
will be provided at the first session to keep provided materials
together for review. The CBT-I sessions will be audio recorded
to assess treatment integrity if the subject agrees.
CBT-I intervention fidelity will be assessed by an independent
CBT-I expert who will use a scoring sheet to assess CBT-I
provider’s compliance in utilizing the manual to deliver the
CBT-I. The CBT-I provider will be scored on 5 scales from 0
(poor) to 6 (excellent) based on (1) how they address immediate
concern, (2) how they explain the outline of the session, (3)
how they discuss the sleep diary outcomes, (4) their adherence
in providing the intervention, and (5) their competency in
delivering each session.
Control Group
Participants allocated to the HE group will meet with the CBT-I
provider weekly for 1 hour of HE sessions. The HE sessions
include several components including brief sleep hygiene, foot
care, diabetes classifications, healthy diet, and physical activity.
During all sessions, subjects will be encouraged to engage in
discussion through open questions about their experience of
diabetes and lifestyle as well as their comprehension of the
provided materials. Similar to the CBT-I group, session tracking
sheets will be used to track new difficulties or concerns and
provided education.
Outcomes
Demographic and Clinical Variables
Age, race, ethnicity, sex, marital status, education, employment,
diabetes duration, medication list, and body mass index will be
gathered at the first assessment session.
Sleep Outcomes
Insomnia Severity
The Insomnia Severity Index (ISI) is a self-report measure
designed to evaluate the nature, severity, and impact of insomnia
[108]. The ISI is a valid and reliable measure of clinical
insomnia and involves 7 questions, each rated on a 0 to 4 Likert
scale. Total scores range from 0 to 28, with higher scores
indicating greater insomnia severity [108]. The internal
consistency of ISI was excellent for community sample and
clinical sample (alpha=.90 and alpha=.91, respectively). The
cutoff score>10 on the ISI provided optimal sensitivity and
specificity for the detection of insomnia based on the Diagnostic
and Statistical Manual of Mental Disorders, fifth edition,
diagnostic criteria (area under the curve=0.82; 95% confidence
interval 0.78-0.86) [109].
Sleep Variability
The Actigraph device is a small, noninvasive device worn on
the nondominant wrist that records limb movements using
electrical impulses, and it has been validated for use in people
with insomnia [110]. Sleep parameters including SE, SL, TST,
and WASO will be measured. In addition to the Actigraph, we
will also use a sleep diary to allow for better estimation of the
time in and out of bed as well as for removing invalid sleep
periods that are measured by the Actigraph [111]. The sleep
diary will also measure total time spent in bed, total time spent
out of bed, number of awakenings, number of bathroom visits,
and glucose level before and after sleep time. All sleep
parameters will be presented in averages of 7 nights and the
coefficient of variance (CV) will be calculated using the
following equation (CV=standard deviation/mean×100) for each
objective and subjective sleep parameters—SE, SL, TST, and
WASO—to analyze objectively within-subject variability of
nighttime sleep of 7 nights. This calculation will provide a
percentage value with a higher number suggesting higher
variability [112].
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The Epworth Sleepiness Scale (ESS) uses 8 items on a 4-point
Likert scale, where the subjects rate how likely they would be
to fall asleep in 8 different states of daily activities. The ESS
has demonstrated satisfactory psychometric properties such as
test-retest reliability (r=.82) and internal consistency (alpha=.88).
The cutoff point is ≥10 to distinguish between normal from
pathological sleepiness [24].
Sleep Quality
The Pittsburgh Sleep Quality Index (PSQI) is a validated 19-item
questionnaire that differentiates between poor and good sleepers.
The PSQI uses 7 items on a 4-point Likert scale, and it yields
a global sleep quality score that ranges from 0 to 21. Poor
sleepers have scores >5, with this cutoff global PSQI score
providing satisfactory sensitivity (89.6%) and specificity
(86.5%). In our study, we will use a 3-factor scoring model for
the PSQI (SE, perceived sleep quality, and daily disturbances),
which has been tested and validated [113]. Sleep duration and
SE were classified under the SE factor; subjective sleep quality,
SL, and the use of sleeping medications were categorized under
the perceived sleep quality factor; and the frequency of sleep




The diabetic care profile (DCP) uses items on 5-point Likert
scales to evaluate the frequency of symptoms related to diabetes.
The DCP is a validated instrument that measures self-reported
diabetes control and psychological and social factors associated
with the management of diabetes [114,115].
Glycemic Control
A1c will be determined using the hemoglobin A1c test by a
disposable blood finger stick test using (A1cNow+ kit; TMS
Company). The A1c indicates the average blood glucose level
of people with diabetes over the previous 2 to 3 months and
represents the current management of diabetes [116]. Every 1%
drop in A1c is associated with improved outcomes with no
threshold effect [117].
Glucose Level
Random glucose levels will be measured using glucose meter
(Contour Next EZ Blood Glucose Monitoring System, Model
7252). The results of glucose level will be presented in




Fatigue symptoms will be measured using the Fatigue Severity
Scale (FSS), which is a 9-item questionnaire that has been
validated in people with diabetes [119]. The FSS measures
fatigue across 5 subscales including motivation, exercise,
interference with work, family, or social life. These subscales
have total scores where a score <4 indicates no fatigue, scores
between 4 and 4.9 indicate moderate fatigue, and a score >5
indicates severe fatigue [119].
Pain Severity Symptoms
The BPI is a valid and reliable measure to assess painful diabetic
peripheral neuropathy [120]. We measured the means of the
severity scale and the interference scale of the BPI.
Depression Symptoms
The BDI has high reliability and good validity [121,122]. It
contains 21 self-reported items on a 3-point Likert scale, with
scores ≥21 indicating severe depression symptoms [121,122].
Anxiety Symptoms
The GAD-7 uses 7 items on a 3-point Likert scale. The total
score of the GAD-7 ranges from 0 to 21, with higher scores
indicating severe anxiety symptoms. It has been shown to be
highly sensitive and specific for the detection of anxiety
symptoms, and it is correlated with other anxiety scales [123].
Participant Timeline
All measurements will be performed at baseline and 1 week
after treatment completion (Figure 3). Participants who wish to
withdraw during the intervention will be asked to complete the
reassessment session.
At initial contact with a potential subject, a phone screening or
diabetes clinic interview will be conducted by a member of the
research team to determine whether an individual qualifies to
progress to an in-person screening for the study. The phone
screening interview assesses participant eligibility according to
age, self-report of T2D diagnosis, insomnia severity, ability to
understand English, STOP-Bang score, RLS Diagnostic Index,
pregnancy status, alcohol use, night-shift work, and undiagnosed
neurological disorders.
Individuals passing the phone screening will be scheduled for
an in-person screening session to assess eligibility according to
symptoms of pain, depression, and anxiety.
Subjects will undergo the consent process in a private room at
KUMC before completing any of the in-person screening
assessments. Individuals passing the in-person screening will
then immediately begin baseline assessment.
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Figure 3. Consort of the project. A1c: glycemic control; BDI: Beck Depression Inventory; BPI: Brief Pain Inventory; CBT-I: cognitive behavioral
therapy for insomnia; DCP: diabetic care profile DSCB: diabetes self-care behavior; ESS: Epworth Sleepiness Scale; GAD-7: Generalized Anxiety
Disorder–7; ISI: Insomnia Severity Index; PSQI: Pittsburgh Sleep Quality Index; and T2D: type 2 diabetes.
Sample Size
To detect the effect of CBT-I on people with T2D and symptoms
of insomnia, the change in pre-post ISI was used to determine
sample size. Pre-post changes using the minimal clinically
meaningful difference of 8 points for the ISI in a previous study
[124] were used to estimate the effect size. This calculation
resulted in 10 participants per group to reject the null hypothesis
of equal means when the population mean difference equals 8
with a standard deviation of 7. We accounted for an expected
attrition rate of 40%, which indicated 28 subjects in both groups
to detect the significant difference between groups after allowing
for attrition at a .05 significant level and power of .80.
Recruitment
Subjects will be recruited from diabetes and sleep clinics at
KUMC, university advertisements, community centers in Kansas
City, flyers, personal referrals and newsletters, and a registry
of patients from KUMC who have signed up to be contacted
about potential research opportunities.
Assignment of Interventions (for Controlled Trials)
Allocation Sequence Generation
We will use random mixed block size randomization [125] to
assign participants to either CBT-I (n=14) or HE (n=14) groups.
Participants will be stratified by age where 62 years is the value
that will stratify participants into either the older (63-75 years)
or the younger (40-62 years) age group. The reason we chose
age as a blocking variable is that the impact of age on sleep is
more pronounced than gender [126], as older adults often have
poorer [127] and lower slow wave [128] sleep, as compared
with young adults.
Allocation Concealment Mechanism
Participant allocations will be placed in sealed envelopes. The
envelopes are prepared by a research assistant, who withholds
this information from the CBT-I provider. After finishing the
baseline assessment, participants will be asked to open the sealed
envelope to disclose their group allocation. Microsoft Excel
will be used to create the randomization lists.
Allocation Implementation
A computer will be used to generate the random mixed block
size randomization sequences. Results of the generator will be
concealed from the assessor and CBT-I provider. Participants
will be asked to open the sealed enveloped after informed
consent and baseline assessment are completed.
Blinding
The assessor, who is blinded to group allocation, will score the
Actigraph data. The assessor will have experience in scoring
criteria and no involvement in providing the interventions. The
CBT-I provider will not be blinded in this study.
Data Collection, Management, and Analysis
Data Collection and Methods
Insomnia severity (primary outcome); sleep variability; fatigue;
DSCB; A1c; daytime sleepiness; sleep quality; glucose levels;
and symptoms of depression, anxiety, and pain will be measured
a week before and after the intervention.
Data Management
All study-related procedure will be performed at Georgia
Holland laboratory in Hemenway Life Sciences Innovation
Center on the KUMC campus. All obtained participant records
will be kept in locked cabinet inside the Georgia Holland
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laboratory. Electronic study data will be saved in the KUMC
Research Electronic Data Capture system. For voice records,
all tapes will be saved on a secure university-supported network
drive.
Statistical Methods
A chi-square test will be used to compare between-group
differences in categorical variables. Independent 2-sample t
tests will be used to compare differences in continuous
between-group demographic characteristics and clinical
variables.
For the main analysis, the effect of the CBT-I intervention will
be investigated by calculating change scores for the insomnia
severity; DSCB; A1c; fatigue; sleep quality; daytime sleepiness;
and symptoms of depression, anxiety, and pain. In addition, for
variability of each sleep outcomes (SE, SL, TST, and WASO),
CV of 7 nights before the pre- and postintervention assessments
will be calculated, and change scores will be calculated. Then,
independent sample t tests will be utilized to investigate the
between-group difference in the change score means of all
outcomes. A completer vs noncompleter analysis will be
performed. For all analyses, alpha level will be set at .05.
Owing to the complex relationship between insomnia and T2D,
some factors are needed to be controlled to fully investigate the
relationship. Owing to the small sample size and possible
covariates that might not be included in the power calculation,
these complex relationships will be investigated using
exploratory analyses. Post hoc analysis using the type and
number of medications will used to address the potential
confounding effects on the outcomes. Univariate linear
regression will be used to control for demographic and clinical
variables (covariates). The decision to perform these analyses
with demographic and clinical variables will be made if there
are significant between-group differences at baseline in
depression symptoms, anxiety symptoms, pain symptoms,
gender, diabetes duration, or body mass index. Mixed models
will be used to account for the correlation between times in pre-
and posttest (7 nights as random factor) sleep variability (as
dependent variable) and facilitate adjustment for covariates to
compare the difference in sleep variability between the CBT-I
and HE groups (groups as fixed factor). Covariates will be
determined if there is a difference in the baseline assessment
for demographic and clinical outcomes. Those participants who
are treated with CPAP will be asked to report their compliance
using CPAP during baseline and postintervention assessments.
Subjects who are using VPAP will be given a modified sleep
diary to check off nights of CPAP compliance during the
assessment sessions. An exploratory subanalysis will be utilized
to investigate the difference in insomnia severity between
compliance and noncompliance with CPAP. Noncompliance is
defined as (1) missing more than 2 nights during the 7 nights
period that the participant is wearing the Actigraph or (2) using
the CPAP for <4 hours per night during this study.
Monitoring and Ethics
Data Monitoring
The primary investigator will review the dataset at least
semiannually. The primary investigator’s evaluation will be
focused on the quality of data collection and data management.
In addition, the investigators will review data in an ongoing
manner for accuracy, both at a time when these data are entered
into the database and during analysis.
Harms
During the pre and postassessment sessions, testing will be
stopped if the subjects show signs of low blood sugar (<70
mg/dL) or if signs of dizziness or headache are noted by the
assessor or reported by the participant. During assessment
sessions, participants also will be instructed to stop the test at
any time for a rest break, as often as needed.
There is a risk of skin redness may be associated with wearing
the Actigraph for 1 week. The risks of wearing the Actigraph
are nearly the same as wearing a wrist watch. If skin redness or
inflammation happened, subjects may remove the Actigraph
and immediately report the symptoms to research personnel. In
addition, there is a risk of minor electrical shock if the Actigraph
is damaged. If damage to the Actigraph occurs, subject will be
asked to return it to our lab, and they will be given a
replacement.
Initially, participating in a CBT-I intervention may have an
increase in sleepiness, which may impact participants’ fatigue,
thinking ability, or functional abilities. It is anticipated that this
increase in sleepiness will be temporary and should help
participants sleep better in the long term.
During the in-person screening session, if suicidal intent is
identified through either the BDI (question number 9, with a 2
or a 3) or verbal statement from the participant, a suicidality
protocol will be followed. The suicidality protocol is designed
to provide the researcher with contact information for
appropriate psychology and psychiatric professionals at KUMC.
Research Ethics Approval
The study will be performed in accordance with KUMC’s
Institutional Review Board and Human Subjects Committee.
No individuals will be excluded based on sex, race, or ethnicity.
Interested participants will be administered a structured
screening interview to determine their eligibility for the study.
During the consent session, all interested participant will be
informed about the study’s objective, risks, procedure, and
potential benefits (or lack thereof).
Consent or Assent
Consent will be obtained in Georgia Holland Health Exercise
and Aging Lab on the main campus of KUMC. Participants will
be encouraged to ask any questions about the study as much as
they need, and members of research study will answer their
questions. In addition, participants will be informed if there is
any change in the protocol to sign a new consent form.
Confidentiality
All data will be deidentified and stored on the KUMC research
private drive, which will be secured and backed up every night.
The working dataset will be stored on a password-protected
computer in the primary investigator’s laboratory, with access
restricted to study researchers who are actively working with
these data. All subject files and documents will be stored in a
locked cabinet.
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A total of 28 participants with T2D and insomnia symptoms
recruited from February 2019. This study currently completed
the recruitment stage. The completion date for the study was
September 2019. Our results will describe the changes in
insomnia severity; sleep variability; fatigue; A1c; DSCB; and
severity of depression, anxiety, and pain. We will report our




Our study will be the first in conducting an RCT using CBT-I
for people with T2D. If this study indicates that 6 sessions of
CBT-I are effective in improving sleep and diabetes outcomes
in people with T2D and insomnia symptoms when compared
with HE, CBT-I could be implemented as an effective and safe
treatment for this population, although more research will be
needed to verify the findings of this pilot RCT.
Pharmacological interventions for sleep difficulties have shown
harmful effects on people with T2D. There is a need to better
understand safe intervention benefits in people with T2D. This
study will contribute to the management of T2D using
behavioral sleep intervention as an effective and safe treatment
for people with insomnia symptoms. The results will contribute
to the literature by examining the effect of CBT-I on both sleep
and diabetes outcomes. This will help in understanding the
effectiveness of short duration intervention designed for people
with insomnia symptoms.
Strengths
The study strengths include utilizing important methods for
people with T2D, such as objective measures, design, and safe
intervention. Determining sleep variability using objective and
subjective measures will accurately detect sleep improvement
after an intervention. Using comparative groups to understand
the effect of CBT-I on insomnia symptoms, sleep variability,
fatigue, and diabetes-related health outcomes will add new
information to the literature and improve the understanding of
clinical conditions. Previous studies recommend optimizing the
sleep quality and quantity for people with comorbidities.
Understanding the effect of CBT-I in people with T2D will
expand the generalizability of using this type of interventions.
Limitations
Some limitations in this protocol might be important to consider
in future studies. First, we will not confirm the diagnosis of
T2D using the current American Diabetes Association
guidelines. However, a study showed that the specificity of
prevalent self-reported diabetes and incident self-reported
diabetes were 84% and 97% and sensitivity of 55% and 80%,
respectively, compared with fasting glucose, A1c, and/or
medication use [100]. In addition, a study suggests that
self-report of diabetes is sufficiently accurate [101]. To
overcome this limitation, we will review the medication list to
confirm T2D diagnosis during the in-person screening visit.
Second, we might not able to distinguish the improvement in
insomnia severity between controlled vs uncontrolled diabetes,
which might be examined under future sleep behavioral therapy
studies. Third, our study will be powered based on the ISI, and
we recommend future studies to choose a diabetes outcome for
conducting the power calculation. Fourth, the participants will
not be blinded in the study, which may result in the control
group participants looking for CBT-I providers outside of the
study. We will monitor any change in pharmacological or
nonpharmacological treatments during the postintervention
session to help explain unexpected results. It is possible,
however, that some participant may not reveal this information,
which might influence the outcomes. Finally, we will not be
able to monitor CPAP compliance during the intervention, but
we will follow up with people in the CBT-I group to ensure no
issue wearing a CPAP machine every session.
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